Davey Legendre, PharmD, MBA, BCPS-AQID, Vice President of Clinical Infectious Diseases at CPS has co-authored an article – Secnidazole: a treatment for trichomoniasis in adolescents and adults – published in Expert Review of Anti-Infective Therapy, in the June 1, 2022 edition.

Co-authors include Christina A. Muzny, MD and Olivia T. Van Gerwen, MD, both affiliated with the University of Alabama at Birmingham Hospital.

Introduction

Single-dose 2-g oral secnidazole (SEC), newly approved by the U.S. Food and Drug administration (FDA) for treatment of trichomoniasis, is a potent 5-nitroimidazole with selective toxicity against various micro-organisms. It has been used internationally to treat trichomoniasis, bacterial vaginosis, and other infections for decades.

Trichomoniasis is the most common non-viral sexually transmitted infection worldwide and is associated with significant morbidity. In comparison to the only other FDA-approved treatments for trichomoniasis in the United States - metronidazole and tinidazole - SEC has favorable pharmacokinetics, including a longer half-life and a lower minimal lethal concentration.

Areas Covered

The article summarizes the chemistry and pharmacology of SEC and reviews the evidence on its efficacy, tolerability, and safety for the treatment of trichomoniasis.

Key Points from Advance Bills

SEC is an efficacious, well-tolerated, and safe treatment for patients aged ≥12 years with trichomoniasis. Single-dose administration makes it a favorable treatment option, especially in cases where adherence to multi-dose treatment regimens may be low.

View the abstract here:  https://pubmed.ncbi.nlm.nih.gov/35642509/